Rani Therapeutics Holdings, Inc. (RANI) News

Rani Therapeutics Holdings, Inc. (RANI): $8.28

0.73 (+9.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RANI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 378

in industry

Filter RANI News Items

RANI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RANI News Highlights

  • For RANI, its 30 day story count is now at 5.
  • Over the past 8 days, the trend for RANI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about RANI are LI, NOV and UL.

Latest RANI News From Around the Web

Below are the latest news stories about RANI THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate RANI as an investment opportunity.

Private companies among Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders, saw gain in holdings value after stock jumped 21% last week

If you want to know who really controls Rani Therapeutics Holdings, Inc. ( NASDAQ:RANI ), then you'll have to look at...

Yahoo | November 17, 2022

Rani Therapeutics GAAP EPS of -$0.33

  • Rani Therapeutics press release (NASDAQ:RANI): Q3 GAAP EPS of -$0.33.
  • Cash, cash equivalents, restricted cash equivalents and marketable securities as of September 30, 2022 totaled $98.7 million, compared to cash and cash equivalents of $117.5 million for the year ended December 31, 2021.
...

Seeking Alpha | November 11, 2022

Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates

Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

- RT-102 Phase 1 topline repeat-dose data anticipated in 4Q 2022 - - Announced preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn’s disease and psoriasis - - Announced RT-102 Phase I single-dose topline results - SAN JOSE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics com

Yahoo | November 10, 2022

Rani Therapeutics to Present at the Stifel Healthcare Conference

SAN JOSE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company will present at the Stifel Healthcare Conference taking place on November 15 - 16, 2022. Talat Imran, Chief Executive Officer of Rani, is scheduled to present on Wednesday, November 16 at 9:45 AM EST / 6:45 AM PST. Interested parties can ac

Yahoo | November 9, 2022

Here's Why Rani Therapeutics Holdings, Inc. (RANI) Is a Great 'Buy the Bottom' Stock Now

Rani Therapeutics Holdings, Inc. (RANI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Yahoo | October 28, 2022

Analysts Are Bullish on Top Healthcare Stocks: Veru (VERU), Taysha Gene Therapies (TSHA)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veru (VERU – Research Report), Taysha Gene Therapies (TSHA – Research Report) and Rani Therapeutics Holdings (RANI – Research Report) with bullish sentiments. Veru (VERU) H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Veru yesterday and set a price target of $24.00. The company's shares closed last Wednesday at $12.09. According to TipRanks.

Brian Anderson on TipRanks | October 26, 2022

Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update

- Rani announces preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn’s disease and psoriasis - - RT-102 Phase 1 repeat-dose topline data anticipated in 4Q 2022 - - Initiation of in vivo studies with fully-autonomous RaniPill HC anticipated in 4Q 2022 - SAN JOSE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI

Yahoo | October 24, 2022

Analysts’ Top Healthcare Picks: InflaRx (IFRX), Entera Bio (ENTX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on InflaRx (IFRX – Research Report), Entera Bio (ENTX – Research Report) and Rani Therapeutics Holdings (RANI – Research Report) with bullish sentiments. InflaRx (IFRX) H.C. Wainwright analyst Edward White maintained a Buy rating on InflaRx today and set a price target of $8.00. The company's shares closed last Thursday at $2.56. According to TipRanks.

Catie Powers on TipRanks | September 29, 2022

8 Best Stocks to Buy According to Billionaire Marc Lasry

In this article, we will take a look at the 8 Best Stocks to Buy According to Billionaire Marc Lasry. To skip our analysis of Marc Lasry’s profile, investment strategy, and 13F holdings, you can go directly to see the 3 Best Stocks to Buy According to Billionaire Marc Lasry. Avenue Capital Management is a […]

Yahoo | September 27, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5476 seconds.